— Know what they know.
Not Investment Advice

REPL NASDAQ

Replimune Group, Inc.
1W: +5.7% 1M: -18.2% 3M: +13.9% YTD: +46.9% 1Y: +210.4% 3Y: -21.3% 5Y: -59.5%
$13.07
-0.38 (-2.83%)
 
Weekly Expected Move ±6.5%
$11 $12 $13 $14 $15
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 42 · $1.1B mcap · 79M float · 5.95% daily turnover · Short 56% of daily vol

Cash Flow Trends

Operating Cash Flow
-$280M -45.8% ▼
Capital Expenditures
$4M +36.8% ▲
5Y CAGR: +12.0%
Free Cash Flow
-$285M -43.0% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$98M +167.0% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2022FY2023FY2024FY2025FY2026
— Operating Activities —
Net Income-$118M-$174M-$216M-$247M-$314M
Depreciation & Amort.$2M$2M$3M$4M$4M
Stock-Based Comp.$24M$28M$34M$35M$32M
Change in Working Capital$7M$15M$5M$24M-$4M
Other Non-Cash Items$2M$494K-$12M-$8M$1M
Operating Cash Flow-$82M-$128M-$185M-$192M-$280M
— Investing Activities —
Capital Expenditures-$2M-$2M-$6M-$7M-$4M
Acquisitions (Net)-$530$140K$0$0$0
Investment Purchases-$256M-$583M-$490M-$404M-$78M
Investment Sales$256M$443M$592M$386M$393M
Other Investing$530-$140K$0$0$0
Investing Cash Flow-$2M-$143M$97M-$24M$311M
— Financing Activities —
Net Debt Issuance-$264K$28M$15M-$599K$34M
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$0$96M$0$97M$0
Financing Cash Flow$7M$311M$16M$252M$66M
Net Change in Cash-$77M$41M-$72M$37M$98M
Cash End of Period$108M$148M$76M$113M$211M
Free Cash Flow-$85M-$130M-$191M-$199M-$285M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms